Unlocking the Potential of Cell-Specific Promoters: Annogen and VectorY Join Forces in a Groundbreaking Research Collaboration

Annogen is working to create multiple CNS-cell specific promoters that can be used in VectorY programs. This innovative approach will help to further advance the field of neuroscience and give us a better understanding of how our brains function. By harnessing the power of VectorY programs, Annogen is paving the way for a new era of CNS research.

VectorY Therapeutics, a biotech company dedicated to developing pioneering vectorized antibody therapies to treat neurodegenerative diseases, is proud to announce a research collaboration with Annogen, the company behind the cutting-edge SuRE™ technology. Together, they are making strides towards identifying CNS-cell specific synthetic promoters for use in VectorY’s vectorized antibody programs, offering new hope for those suffering from neurodegenerative disorders.

Annogen’s proprietary Survey of Regulatory Elements (SuRE™) technology is revolutionizing gene and cell therapy by functionally annotating the entire human non-coding genome. This groundbreaking technology screens hundreds of millions of DNA elements to identify regulatory elements that control therapeutic gene expression in a cell- or disease-specific manner. Unlike other promoter-identification technologies, SuRE™ is able to functionally test non-coding promoter elements throughout the genome, even in remote sites where activity is regulated. This cutting-edge technology is transforming the way gene and cell therapy is done.

Sander van Deventer, CEO of VectorY, is thrilled to join forces with Annogen to develop cutting-edge, cell-specific promoters that will boost the effectiveness of VectorY’s groundbreaking AAV-vectorized antibody platform. If successful, this could lead to revolutionary treatments for neurodegenerative diseases such as ALS, offering hope to countless patients around the world.

VectorY is revolutionizing the treatment of neurodegenerative diseases with its cutting-edge vectorized antibody therapies. Powered by a unique platform combining therapeutic antibodies, capsids, and production processes, the company is at the forefront of creating precision treatments for ALS, Huntington’s, and Parkinson’s disease. VectorY is leading the way in developing innovative, one-time therapies that can have a transformative impact on the lives of people suffering from these debilitating conditions.

At VectorY, we are revolutionizing the way we approach antibody therapy development with our novel, advanced methods. Our focus on controlling various aspects of vector design, enabled by our partner Annogen’s SuRE™ technology, demonstrates our commitment to optimizing the efficacy of our treatments. We are immensely proud of this collaboration and are excited to continue leveraging cutting-edge techniques to provide the best possible care for our patients.

About VectorY

At VectorY, we are committed to improving the lives of those suffering from neurodegenerative diseases through innovative vectorized antibody treatments. Our platform combines the power of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, unlocking a world of possibilities. Our in-house experts have unparalleled expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience, allowing us to rapidly develop treatments that can modify the course of diseases like ALS and Huntington’s disease. We are proud to offer a longer, better life for those in need.

About Annogen

At Annogen, we are revolutionizing the way gene and cell therapy, as well as recombinant protein production, are conducted. Through our SuRE™ technology, we can identify regulatory DNA elements that can be used to control therapeutic gene expression. Our AIM™ service further enables us to identify favorable gene insertions and the corresponding expression levels for more than 100,000 integrations in parallel, giving Research and Development the power to interpret the human, animal, and plant non-coding genome in unprecedented detail.

Leave a Comment